101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
News, Material Contracts
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News, Articles of Incorporation, Bylaws
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership